Itonis, Inc. Update on Company Direction With Emesyl and Licensing of App for Medical Marijuana Point of Purchase
March 26 2014 - 11:28AM
Marketwired
Itonis, Inc. Update on Company Direction With Emesyl and Licensing
of App for Medical Marijuana Point of Purchase
LAGUNA HILLS, CA--(Marketwired - Mar 26, 2014) - Itonis, Inc.
(PINKSHEETS: ITNS) today issued the following update to its
shareholders:
The Company recently announced that it had entered into a letter
of intent to license a proprietary mobile app from MyECheck, Inc.
to facilitate point of purchase transactions for medical marijuana,
gambling and general retail sales. We are on track to finalize the
licensing details soon. Through our pharmaceutical relationships,
we noticed an unmet demand regarding medical marijuana and the
point of sales from medical suppliers. We believe that there is a
significant revenue opportunity in addressing this demand with
MyECheck's proprietary payment app and connecting it to the medical
marijuana sector.
We also announced that Dr. Charles Hensley approved the Emesyl™
nausea remedy for manufacturing. Dr. Hensley tested the different
samples sent by the manufacturer and has selected the more superior
sample to be used for production.
We are proud and excited about the future in both of these
ventures and we will continue to work hard delivering quality and
profitable products to our customers and shareholders.
We plan to update our shareholders soon on the finalized
licensing with MyECheck, Inc. and the next steps on manufacturing
Emesyl™.
Thank you for your continuing support of the Company.
Mark Cheung CEO / President
About Itonis,
Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5,
2005 under the name of Kenshou, Inc., which later changed to
Itonis, Inc. on December 2, 2005. Please visit
www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact: Itonis, Inc. Email Contact
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Nov 2023 to Nov 2024